BTX161
BTX161, a thalidomide analog, is an effective CKIα degrader. BTX161 mediates human AML cell CKIα degradation more effectively than lenalidomide and activates the DNA damage response (DDR) and p53, while stabilizing p53 antagonist MDM2.
Product Specifications
CAS Number
2052301-24-1
UNSPSC
12352005
Target
Casein Kinase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/btx161.html
Purity
99.20
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C([C@@H](N(CC1=C2C=CC=C1C)C2=O)CCC3)NC3=O
Molecular Formula
C15H16N2O3
Molecular Weight
272.30
References & Citations
[1]Minzel W, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018;175 (1) :171-185.e25.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
V4505SAF-100UG 100 µg
NME2 Antibody / Nucleoside diphosphate kinase B / NDKB
Sign In for Pricing
View Details